Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Alemtuzumab (Primary) ; Anti-CD45 monoclonal antibody (Primary) ; Fludarabine; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACHE
- 28 Jun 2012 Actual patient number is 24 according to ClinicalTrials.gov.
- 28 Jun 2012 Actual patient number is 24 according to ClinicalTrials.gov.
- 28 Jun 2012 Actual end date changed from Oct 2009 to Dec 2006 as reported by ClinicalTrials.gov.